post


  • View from the Trenches: Panel reviews practice-changing presentations from SABCS 2022

    View from the Trenches: Panel reviews practice-changing presentations from SABCS 2022

    On Friday, December 9, experts highlighted the updates from SABCS 2022 that may have an immediate impact for patients and physicians.

  • Year in Review session summarizes important developments in breast cancer

    Year in Review session summarizes important developments in breast cancer

    Andrei Goga, MD, PhD; Shom Goel, MBBS; Marleen Kok, MD, PhD; and Melinda Telli, MD, outlined updates across the spectrum of breast cancer research and clinical practice on Saturday, December 10.

  • Panelists examine key clinical controversies in breast cancer

    Panelists examine key clinical controversies in breast cancer

    Viviana Galimberti, MD, and fellow panelists explored evolving questions around the utility of targeted axillary dissection, the optimal duration of endocrine therapy, and the role of neoadjuvant therapy in triple negative breast cancer during a session Wednesday, December 7.

  • Experts debate current controversies in translational medicine

    Experts debate current controversies in translational medicine

    Hope S. Rugo, MD, opened a discussion session on Thursday, December 8, which explored different opinions on the future of minimum tolerable dose (MTD), randomized trials vs. real-world evidence, and the utility of Ki67 as a clinical biomarker.

  • AACR distinguished lecturer delves into prognosis potential of genomic subtypes of breast cancer

    AACR distinguished lecturer delves into prognosis potential of genomic subtypes of breast cancer

    Charles M. Perou, PhD, spoke Wednesday, December 7, about the importance of quantitative and objective means for measuring the intrinsic subtypes and immune signatures of breast cancer.